Graft-versus-host reactions and bone-marrow transplantation.
Three areas of bone-marrow transplantation have developed particularly rapidly during the past year. First, increasing numbers of bone-marrow transplants using matched unrelated donors or HLA-mismatched family members have been successfully performed. Second, trials of recombinant hemopoietic growth factors have shown these agents can accelerate hemopoietic recovery after bone-marrow transplant and reduce the incidence of infections and other post-transplant complications. But potentially the most important advances have come in a series of separate observations, which in conjunction suggest mechanisms by which the anti-leukemic activity of an allograft may be separated from its ability to induce graft-versus-host disease.
Brenner
M K
MK
St Jude Children's Research Hospital, Memphis, Tennessee.
Heslop
H E
HE
D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D017252:CD3 Complex; D006087:Graft vs Host Reaction; D006410:Hematopoiesis / Q000187:drug effects; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006648:Histocompatibility; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D007938:Leukemia / Q000276:immunology / Q000601:surgery; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D011828:Radiation Chimera; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016298:Hematopoietic Cell Growth Factors; D011948:Receptors, Antigen, T-Cell; D011994:Recombinant Proteins